order
nidoviral
consist
two
famili
envelop
positivesens
singlestrand
rna
virus
arterivirida
coronavirida
potenti
human
pathogen
found
two
genera
coronavirida
coronaviru
toroviru
human
coronavirus
hcov
initi
discov
caus
respiratori
tract
infect
two
princip
pathogen
interest
coronavirus
rekindl
global
outbreak
sever
acut
respiratori
syndrom
sar
result
case
global
casefat
rate
aetiolog
agent
sar
found
novel
coronaviru
current
name
unlik
sever
ill
high
mortal
rate
pandem
potenti
sarscov
prompt
rapid
search
effect
antivir
therapi
follow
discoveri
sarscov
coronavirus
subsequ
recogn
common
caus
communityacquir
respiratori
infect
especi
two
novel
agent
found
human
caus
acut
respiratori
diseas
lesser
sever
mortal
sarscov
especi
immunocompet
host
howev
activ
surveil
shown
new
virus
also
contribut
sever
communityacquir
transmiss
sarscov
occur
primarili
larg
droplet
contact
possibl
airborn
transmiss
rare
situat
risk
transmiss
reflect
atrisk
popul
wild
anim
handler
southern
china
household
contact
healthcar
worker
last
group
especi
suscept
account
global
case
aerosolgener
procedur
particularli
riski
basic
reproduct
number
infect
earli
epidem
emerg
sar
late
reemerg
late
affect
patient
anim
handler
sporad
case
afterward
relat
expos
laboratori
worker
therefor
patient
relev
exposur
histori
develop
rapidli
deterior
pneumonia
must
isol
contact
droplet
possibl
airborn
precaut
till
serial
test
respiratori
faecal
sampl
collect
present
peak
viral
shed
day
onset
ill
neg
sarscov
addit
antibodi
detect
anoth
confirmatori
test
diagnos
sar
howev
definit
diagnosi
serolog
requir
demonstr
rise
antibodi
titr
pair
sera
clinic
laboratori
indirect
immunofluoresc
antibodi
assay
commonli
use
rather
neutral
assay
latter
cumbersom
requir
handl
live
virus
also
possibl
diagnos
sar
detect
viral
antigen
serum
use
monoclon
polyclon
antibodi
n
protein
sensit
assay
invers
proport
time
onset
ill
serum
antibodi
titr
sensit
much
lower
test
nonserum
clinic
specimen
tradit
effect
antivir
agent
coronavirus
initi
effort
focus
use
current
avail
drug
either
convent
antivir
agent
nonantivir
inhibitori
effect
sarscov
sarscov
better
character
term
virolog
pathogenesi
attempt
made
target
specif
pathway
viral
molecul
use
novel
compound
anoth
approach
therapi
use
agent
augment
immun
system
provid
specif
antibodi
use
passiv
immun
tabl
summari
agent
test
undergon
clinic
trial
recent
note
none
potenti
antivir
agent
undergon
random
control
clinic
trial
assess
efficaci
pulmonari
patholog
sar
consist
promin
inflamm
diffus
alveolar
damag
presenc
multinucl
pneumocyt
squamou
metaplasia
epithelium
sometim
bronchiol
obliteran
organ
pneumonialik
lesion
viral
particl
commonli
seen
within
pneumocyt
haemophagocytosi
sometim
seen
absenc
solid
inform
base
control
trial
import
aspect
manag
sar
ventilatori
support
togeth
use
antibacteri
agent
necessari
control
secondari
bacteri
infect
use
noninvas
ventil
initi
ventilatori
support
sar
patient
associ
reduc
intub
need
mortal
cohort
patient
hong
kong
systemat
survey
preval
bacteri
coinfect
present
incid
nosocomi
superinfect
seri
patient
develop
nosocomi
bacteraemia
catheterrel
sepsi
nosocomi
pneumonia
due
stenotrophomona
maltophilia
klebsiella
pneumonia
escherichia
effect
antivir
therapi
control
viral
replic
henc
tissu
damag
inflamm
highli
desir
role
antivir
therapi
support
fact
viral
load
posit
correl
develop
organ
dysfunct
key
organ
replic
sarscov
lung
pneumocyt
alimentari
tract
enterocyt
anoth
issu
consid
antivir
therapi
sar
time
initi
treatment
viral
load
respiratori
tract
increas
first
day
onset
diseas
decreas
thereaft
coincid
seroconvers
therefor
even
antivir
start
day
onset
symptom
treatment
still
potenti
use
halt
progress
infect
provid
agent
potent
enough
inhibit
viral
replic
although
immunomodulatori
wide
use
sar
epidem
avoid
excess
tissu
damag
due
cytokin
dysregul
benefit
conclus
studi
use
corticosteroid
associ
increas
plasma
viral
complic
includ
opportunist
infect
aspergillosi
late
sequela
includ
avascular
osteonecrosi
occur
patient
cohort
hong
initi
infect
first
step
entri
viral
particl
suscept
host
cell
sarscov
enter
host
cell
bind
spike
protein
angiotensinconvert
enzym
neutral
antibodi
shown
protect
anim
studi
specif
neutral
antibodi
unlik
present
gener
popul
onset
new
epidem
neutral
antibodi
elicit
effect
vaccin
activ
area
research
altern
passiv
immun
achiev
use
convalesc
plasma
sar
patient
use
small
number
sar
patient
hong
kong
taiwan
nonrandom
fashion
initi
outbreak
clinic
benefit
includ
decreas
plasma
viral
load
copiesml
undetect
level
h
plasma
theoret
possibl
plasma
contain
neutral
antibodi
may
harvest
individu
immun
sarscov
vaccin
howev
whether
plasma
individu
contain
therapeut
level
antibodi
unknown
subsequ
variou
human
monoclon
antibodi
protein
shown
abl
neutral
viru
therefor
may
potenti
use
therapeut
prophylact
purpos
anoth
approach
inhibit
viral
entri
fusion
use
synthet
peptid
small
molecul
block
interact
protein
exampl
includ
peptid
repres
differ
region
recombin
protein
target
heptad
repeat
protein
quercetin
major
target
antivir
therapi
proteas
coronavirus
main
proteas
sarscov
essenti
viral
replic
lopinavirritonavir
kaletra
earliest
combin
use
treatment
sar
patient
main
antivir
activ
resid
lopinavir
compon
seri
sar
patient
treat
lopinavirritonavir
plu
ribavirin
initi
regimen
hong
kong
treatment
group
lower
incid
advers
outcom
control
group
receiv
ribavirin
term
overal
death
rate
intub
rate
rate
use
mean
dose
anoth
hong
kong
seri
sar
patient
use
lopinavirritonavir
plu
ribavirin
associ
lower
incid
acut
respiratori
distress
syndrom
nosocomi
infect
use
corticosteroid
death
lower
viral
load
nasopharyng
aspir
higher
peripher
lymphocyt
count
compar
histor
control
receiv
ribavirin
recent
nelfinavir
also
found
antivir
activ
sarscov
vero
cell
although
reduc
viral
load
lung
infect
benefici
effect
proteas
inhibitor
may
due
mechan
addit
direct
inhibit
viral
replic
vitro
protein
sarscov
appar
contribut
develop
apoptosi
host
proteas
inhibitor
shown
potent
modul
apoptosi
hiv
infect
immunomodulatori
action
increasingli
recogn
import
benefit
proteas
inhibitor
treatment
hiv
whether
proteas
inhibitor
demonstr
similar
antiapoptot
effect
sarscov
infect
remain
confirm
therefor
consider
use
proteas
inhibitor
clinic
trial
set
treatment
sar
given
prioriti
futur
purin
nucleosid
analogu
ribavirin
broadspectrum
antivir
agent
test
use
treatment
sar
sinc
earli
phase
outbreak
standard
regimen
ribavirin
set
adult
dosag
mgkg
iv
everi
h
day
mgkg
iv
everi
h
day
follow
mg
oral
everi
h
total
day
g
iv
load
follow
g
iv
everi
h
day
mg
iv
everi
h
day
use
g
oral
one
dose
follow
g
oral
everi
h
mg
iv
everi
h
toler
oral
medic
antivir
activ
attribut
inhibit
guanosin
triphosph
synthesi
viral
rna
polymeras
activ
addit
releas
proinflammatori
cytokin
also
reduc
ribavirin
vitro
activ
ribavirin
sarscov
highli
variabl
depend
type
cell
use
antivir
assay
test
vero
cell
ribavirin
demonstr
littletono
activ
sarscov
presum
due
lack
phosphoryl
ribavirin
cell
line
howev
ribavirin
clinic
achiev
concentr
possess
signific
inhibitori
activ
test
cell
line
anim
studi
ribavirin
clinic
benefit
ribavirin
alon
case
seri
likewis
uncertain
anaemia
main
advers
reaction
associ
use
ribavirin
canadian
cohort
patient
receiv
ribavirin
evid
doserel
haemolyt
anaemia
hypomagnesaemia
develop
hypocalcaemia
hypocalcaemia
although
ribavirin
alon
unlik
possess
substanti
antivir
activ
clinic
use
dosag
may
consid
use
combin
agent
especi
type
interferon
synergist
activ
ribavirin
test
therefor
use
ribavirin
infect
undertaken
clinic
set
part
combin
therapi
interferon
promis
agent
control
sarscov
infect
larg
number
interferon
belong
three
class
test
antivir
activ
sarscov
vitro
anim
model
consist
shown
activ
vitro
appear
activ
three
class
interferon
uncontrol
clinic
studi
use
corticosteroid
interferon
synthet
appear
result
improv
oxygen
rapid
resolut
chest
radiograph
certain
unconvent
agent
investig
antivir
activ
sarscov
chloroquin
one
better
studi
compound
possess
vitro
antivir
activ
sarscov
antiinflammatori
properti
chloroquin
postul
benefici
treatment
mechan
action
chloroquin
unknown
may
involv
alter
glycosyl
endosom
ph
antiparasit
agent
extract
herbal
medicin
eg
glycyrrhizin
baicalin
nonsteroid
antiinflammatori
agent
indomethacin
report
inhibit
sarscov
experi
clinic
anim
studi
agent
lack
develop
new
therapeut
agent
human
use
lengthi
process
unlik
immedi
benefit
wake
new
epidem
due
novel
pathogen
appropri
use
exist
agent
viabl
option
circumst
base
avail
inform
suitabl
candid
clinic
trial
event
anoth
outbreak
sar
appear
proteas
inhibitor
lopinavir
nelfinavir
interferon
interferon
interferon
interferon
interferon
convalesc
plasma
stock
institut
hong
kong
red
cross
blood
transfus
servic
use
success
uncontrol
clinic
trial
efficaci
support
laboratori
data
combin
therapi
anoth
possibl
fulli
explor
chloroquin
ribavirin
possibl
agent
consid
regard
proteas
inhibitor
combin
ribavirin
anoth
option
clinic
studi
addit
obviou
use
treatment
sarscov
infect
effect
antivir
could
potenti
import
prophylaxi
expos
individu
laboratori
healthcar
worker
well
prevent
outbreak
institut
although
studi
address
safeti
effect
antivir
prophylaxi
consid
situat
healthcar
worker
expos
aerosolgener
procedur
exposur
high
viral
load
laboratori
accid
circumst
risk
transmiss
highest
epidem
postepidem
period
intranas
interferon
use
success
prevent
experiment
coronaviru
rhinoviru
upper
respiratori
tract
infect
mode
chemoprophylaxi
warrant
studi
use
convalesc
plasma
anoth
option
prophylaxi
although
test
clinic
intranas
system
interferon
convalesc
plasma
prophylaxi
consid
face
new
outbreak
agent
rel
safe
major
caution
use
antibodi
immunoprophylaxi
possibl
enhanc
viral
infect
antibodi
situat
occur
felin
activ
immun
sarscov
attempt
number
approach
includ
use
inactiv
whole
virus
recombin
protein
fragment
subunit
dna
vaccin
viral
vector
carri
target
neutral
antibodi
main
correl
immun
protect
efficaci
candid
vaccin
mainli
studi
anim
far
vaccin
enter
phase
human
sarscov
unduli
resist
chemic
disinfect
alcohol
sodium
hypochlorit
heat
min
min
surviv
faecal
respiratori
specimen
day
room
temperatur
use
common
disinfect
hospit
laboratori
adequ
howev
fact
sar
case
occur
healthcar
worker
mean
infect
control
within
hospit
crucial
compon
manag
addit
last
case
sar
occur
involv
three
incid
singapor
taiwan
beij
laboratoryacquir
case
postoutbreak
period
incid
relat
failur
disinfect
accid
possibl
breach
biosafeti
practic
gener
contact
droplet
precaut
quintessenti
infect
control
measur
wherea
airborn
precaut
necessari
aerosolgener
procedur
bronchoscopi
import
person
hygien
could
also
import
commun
set
intrafamili
transmiss
sar
epidem
occur
household
member
secondari
attack
rate
rang
toronto
singapor
hong
kong
two
cohort
prolong
contact
index
patient
risk
factor
transmiss
interestingli
toronto
seri
also
show
hand
hygien
practic
may
also
affect
risk
transmiss
earli
recognit
index
case
shorten
durat
exposur
mainten
good
person
hygien
prudent
measur
minim
famili
spread
infect
studi
antivir
therapi
coronavirus
sarscov
scarc
clinic
trial
therapi
infect
caus
limit
vitro
data
suggest
intraven
immunoglobulin
heptad
repeat
peptid
sirna
chemic
may
inhibitori
activ
saikosaponin
group
oleanan
deriv
certain
medicin
plant
inhibitori
none
declar
